A 2024 network meta-analysis pooling 28 trials and 23,622 participants found that even tirzepatide 5 mg produced more weight loss than every studied semaglutide dose: 5.27 kg of loss at 5 mg tirzepatide versus a range of 2.52 to 4.97 kg across semaglutide doses from 0.5 to 2.0 mg
Key takeaways Retatrutide isn't approved yet and isn't expected to launch in the UK until at least mid-2026 In clinical trials, target doses ranged from 0.5mg to 12mg weekly, with the most common being 4mg, 8mg, 9mg and 12mg Different dosing schedules were tested, with most people starting at 2mg and escalating every 4 weeks The 12mg dose produced the most weight loss (up to 28.7% after 68 weeks) Starting at 2mg rather than 4mg helped reduce side effects during escalation First to know Get an email the day retatrutide launches in the UK
If youre constipated after starting Mounjaro, youre not alone
[24] This is why multi-strain, multi-genus formulations make biological sense
FAQs What should I track to measure progress on GLP-1 therapy
Your treatment plan is flexible and determined by your healthcare provider